Review anchor
Isocitrate dehydrogenase [NADP] cytoplasmic
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Isocitrate dehydrogenase [NADP] cytoplasmic
CHEMBL2007625
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Isocitrate dehydrogenase [NADP] cytoplasmic as ChEMBL target CHEMBL2007625, mapped to UniProt O75874. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2007625
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
O75874
Isocitrate dehydrogenase [NADP] cytoplasmic
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Isocitrate dehydrogenase [NADP] cytoplasmic matters
Isocitrate dehydrogenase [NADP] cytoplasmic is reviewed as Isocitrate dehydrogenase [NADP] cytoplasmic (UniProt O75874); Isocitrate dehydrogenase [NADP] cytoplasmic shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 8 approved drugs, 39595 compounds, and 482 assays, with lead potency reaching pChEMBL 10.4.
Protein context
Isocitrate dehydrogenase [NADP] cytoplasmic
Isocitrate dehydrogenase [NADP] cytoplasmic Sequence length is 414 aa.
Review this target as Isocitrate dehydrogenase [NADP] cytoplasmic, mapped to UniProt O75874. Sequence length is 414 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O75874
Protein
Disease context
acute myeloid leukemia
Isocitrate dehydrogenase [NADP] cytoplasmic shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BAY1436032, IDH305, IVOSIDENIB.
Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include BAY1436032, IDH305, IVOSIDENIB, OLUTASIDENIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
4 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 8 approved drugs, 39595 compounds, and 482 assays for this target. The dominant activity type is IC50. CHEMBL4279047 is the current potency anchor at pChEMBL 10.4.
Use CHEMBL4279047 as the tractability anchor when discussing potency (pChEMBL 10.4).
Activity source · ChEMBL 36 via Core Engine
8 approved
pChEMBL 10.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Isocitrate dehydrogenase [NADP] cytoplasmic matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O75874, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why acute myeloid leukemia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
39595
Total Compounds
482
Total Assays
8
Approved Drugs
IC50: 13673.0, KI: 158.0, EC50: 14.0, KD: 52.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4279047
|
10.4 | IC50 | Approved |
|
|
No preferred name
CHEMBL4278845
|
9.6 | IC50 | — |
|
|
No preferred name
CHEMBL4283785
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL5633097
|
9.5 | IC50 | — |
|
|
No preferred name
CHEMBL4448475
|
9.4 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
VORASIDENIB
CHEMBL4279047
|
2024 |
|
|
OLUTASIDENIB
CHEMBL4297610
|
2022 |
|
|
IVOSIDENIB
CHEMBL3989958
|
2018 |
|
|
ENASIDENIB
CHEMBL3989908
|
2017 |
Source Header